Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Pending | |||
| Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
| Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
| Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
| Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
| Repatha | evolocumab | Primary hyperlipidemia | Active | |||
| TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
| Remsima | infliximab | Crohn’s disease | Active | |||
| Remsima | infliximab | Ulcerative Colitis | Active | |||
| TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active |
Last Updated : May 2, 2024